Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The event is scheduled for June 15-16, 2026, and the fireside chat will be available on demand starting June 15 at 7:00 a.m. EDT.
The presentation is expected to cover the company's proprietary NSA pipeline, including HLP003, which is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder, will be discussed. Helus Pharma is also advancing an extensive research portfolio of investigational NSAs aimed at addressing unmet needs in mental health.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, focuses on synthetic molecules designed to activate serotonin pathways that promote neuroplasticity. The company's NSAs aim to provide durable improvements in mental health conditions such as depression and anxiety. The company operates in Canada, the United States, the United Kingdom, and Ireland.
For more details, the full press release is available at https://ibn.fm/KsnJW. Investors seeking the latest news and updates about HELP can visit the company's newsroom at https://ibn.fm/HELP.
The H.C. Wainwright Neuro Perspectives Conference is a key industry event that brings together thought leaders and investors to discuss advancements in neuroscience. Helus Pharma's participation underscores its commitment to developing innovative treatments for mental health disorders.
